Table 1 Data sources
Data source | Description | Purpose |
|---|---|---|
Data abstraction | â–ª Data abstracted from clinical delivery tools | â–ª Define profile of screened and initiated on PrEP and whether persons are appropriately put on PrEP |
Technical assistance reports and rapid cycle debriefs. | â–ª Rapid cycle debriefs and TA reports prepared at baseline and 6-monthly | â–ª Document detailed knowledge of process of integration of PrEP delivery and track changes in PrEP implementation processes â–ª Rapid cycle analysis to convey to facilities for quality improvement |
Qualitative interviews: women, healthcare providers, and policy key informants | â–ª Purposefully sampled client and key informants involved in the delivery | â–ª Characterize process of adoption and integration of PrEP delivery and track changes in PrEP implementation processes, including barriers and facilities |
Quantitative surveys | ▪ Healthcare providers ▪ Random cross-sectional exit surveys with women at the end of clinic visit | ▪ Assess acceptability, clinics’ readiness to implement, clinic inner settings ▪ HIV and STI risk perception, characteristics of women accessing through FP clinics, stigma, and satisfaction with services offered. |
Activity-based costing, and time and motions studies | â–ª Primary data collection | â–ª Activity-based costing, and time and motions studies |
Clinic and client flow mapping | â–ª Primary data collection | â–ª Establish baseline flow, track how new services are incorporated in the flow and bottlenecks, and document patient wait-time |
Standardized patient actors | â–ª Standardized clients make unannounced visit to subset of clinics and complete a checklist | â–ª Assess implementation fidelity by documenting type of services offered, quality of services received, and provider attitudes |
Random blood draw | â–ª Dried blood spots collected at ~10% visits on persons using PrEP | â–ª Objective assessment of PrEP adherence (tenofovir levels) |
Nested observational cohort | â–ª Women identified as eligible for PrEP, both who initiate and those who decline | â–ª Detailed individual-level outcomes: HIV risk behaviors, HIV risk perception, HIV incidence, HIV prevention decision making, contraception use, stigma, STI burden, PrEP retention, and reasons for discontinuation |